Some features may not work as expected in this browser. For the full NewsNow experience, please consider updating your browser or trying a different device. Some features may not work as expected.
Please consider updating your browser or device.

Home
Hot Topics
Australia
World
Sport
Business
Entertainment
Science
Technology
Lifestyle

Johnson and Johnson
Pharmaceuticals
GSK
AstraZeneca
AbbVie
Roche
Pfizer
Bayer
Sanofi
Topics

Advertisement

Advertisement

Johnson and Johnson

Share

Top Latest Popular

Johnson & Johnson reports first real-world varipulse pro platform data and 12-month omnypulse platform outcomes for atrial fibrillation treatment at aphrs 2026 Business Wire (Press Release) 21h

Business Wire (Press Release) 21h

The international myeloma foundation launches US myeloma network to accelerate clinical trials, expand access, and improve patient care PR Newswire (Press Release) 20h

PR Newswire (Press Release) 20h

Not Lilly. Not Johnson & Johnson. This stock will be the biggest Healthcare winner of 2026 The Motley Fool 2d

The Motley Fool 2d

Advertisement

Johnson & Johnson announces new data showing Tremfya® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula PR Newswire (Press Release) 4d

PR Newswire (Press Release) 4d

Advertisement

Johnson & Johnson launches next-generation shockwave™ C2 aero fly coronary ivl catheter, cutting ivl treatment time in half Business Wire (Press Release) 3d

Business Wire (Press Release) 3d

Another talc trial opens as j&j gets support for $5.8B Settlement Law.com 3d

Law.com 3d

Advertisement

Advertisement

Latest

Earlier Today

J&J Says Justices' Denial Backs Tossing Fee Suit At 3rd Circ. Law360 00:17

Yesterday

The International Myeloma Foundation Launches US Myeloma Network to Accelerate Clinical Trials, Expand Access, and Improve Patient Care PR Newswire (Press Release) 13:46 Thu, 22 Oct

Johnson & Johnson Reports First Real-World Varipulse Pro Platform Data and 12-Month Omnypulse Platform Outcomes for Atrial Fibrillation Treatment at Aphrs 2026 Business Wire (Press Release) 12:47 Thu, 22 Oct

Wednesday

Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026 The Motley Fool 15:08 Wed, 21 Oct

Is Most-Watched Stock Johnson & Johnson (JNJ) Worth Betting on Now? Zacks 15:06 Wed, 21 Oct

Rapport’s novel oral drug posts Phase II bipolar win Clinical Trials Arena 09:46 Wed, 21 Oct

Tuesday

2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going) The Motley Fool 22:10 Tue, 20 Oct

The Zacks Analyst Blog Highlights Abbott Laboratories, Johnson & Johnson, Stryker, Waste Management and Republic Services Zacks 14:58 Tue, 20 Oct

CHMP backs TALVEY plus daratumumab for earlier myeloma use PharmaTimes 14:31 Tue, 20 Oct

Stock Watch: J&J’s Pharma Strength Has Its Limits Scrip Pharma Intelligence 12:45 Tue, 20 Oct

Advertisement

Advertisement

Advertisement

Advertisement

About our Johnson & Johnson news

Latest news on Johnson & Johnson, the American multinational pharmaceutical, known for developing healthcare, pharmaceuticals, and consumer products. Stay updated on stories about their pioneering medical advancements, including vaccines, treatments, and medical devices. Explore insights into the company’s financial performance, share prices, leadership changes, and global strategies.

NewsNow

Our Sites

NewsNow Nigeria

NewsNow România

NewsNow Australia

Work with us

Publisher Network

Dockside Online IDE

Legal

Subscription Terms

© Copyright 1997 - 2026 NewsNow Publishing Limited. All rights reserved.

Back to Business Pharmaceuticals
- Abbott Laboratories
- AbbVie AbbVie
- AstraZeneca
- Baxter Baxter
- Bayer Bayer
- Boehringer Ingelheim
- Bristol Myers Squibb
- Eli Lilly Eli Lilly
- Genentech Genentech
- GlaxoSmithKline
- Johnson and Johnson
- Merck and Co
- Novartis Novartis
- Novavax Novavax
- Novo Nordisk
- Pfizer Pfizer
- Roche Roche
- Sanofi Sanofi
- Takeda Takeda
- Teva Teva
- Zoetis Zoetis